{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:04:16Z","timestamp":1794243856212,"version":"4.9.0"},"reference-count":157,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Colorectal cancer (CRC) is a major cause of cancer-related morbidity and mortality worldwide, with limited options for patients at advanced stages. Immunotherapy, particularly immune cell-based therapies, has gained significant attention as an innovative approach for targeting CRC. This review summarizes the progress in various immune cell therapies, including DC vaccine, CAR\/TCR-T cells, CAR-NK cells et\u00a0al, each engineered to recognize and attack cancer cells expressing specific antigens. CAR-T cell therapy, which has been successful in hematologic cancers, faces challenges in CRC due to the solid tumor microenvironment, which limits cell infiltration and persistence. CAR-NK cells, CAR-M and CAR-\u03b3\u03b4 T cells, however, offer alternative strategies due to their unique properties, such as the ability to target tumor cells without prior sensitization and a lower risk of inducing severe cytokine release syndrome. Recent advances in lentiviral transduction have enabled effective expression of CARs on NK and \u03b3\u03b4 T cells, providing promising preclinical results in CRC models. This review explores the mechanisms, tumor targets, preclinical studies, and early-phase clinical trials of these therapies, addressing key challenges such as enhancing specificity to tumor antigens and overcoming the immunosuppressive tumor microenvironment. The potential of combination therapies, including immune checkpoint inhibitors and cytokine therapy, is also discussed some as a means to improve the effectiveness of immune cell-based treatments for CRC. Continued research is essential to translate these promising approaches into clinical settings, offering new hope for CRC patients.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1557906","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T04:12:12Z","timestamp":1743480732000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Adoptive immune cell therapy for colorectal cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Chenxiao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongcun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyang","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J For Clin"},{"key":"B2","article-title":"Multidisciplinary team intervention associated with improved survival for patients with colorectal adenocarcinoma with liver or lung metastasis","volume":"8","author":"Chen","year":"2018","journal-title":"Am J Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.142.10.3714","article-title":"Tumor-specific cytolysis by lymphocytes infiltrating human melanomas","volume":"142","author":"Topalian","year":"1989","journal-title":"J Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(08)60874-X","article-title":"Identification of the genes encoding cancer antigens: implications for cancer immunotherapy","volume":"70","author":"Rosenberg","year":"1996","journal-title":"Adv Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ai.2015.12.006","article-title":"Adoptive T-cell therapy for cancer","volume":"130","author":"Yang","year":"2016","journal-title":"Adv Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-558163","article-title":"Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs","volume":"124","author":"Girard-Gagnepain","year":"2014","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2019.157","article-title":"Vectofusin-1 improves transduction of primary human cells with diverse retroviral and Lentiviral pseudotypes, enabling robust, automated closed-system manufacturing","volume":"30","author":"Radek","year":"2019","journal-title":"Hum Gene Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02873","article-title":"Efficient and robust NK-cell transduction with baboon envelope Pseudotyped lentivector","volume":"10","author":"Colamartino","year":"2019","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"11781","DOI":"10.3390\/ijms222111781","article-title":"Cell therapy for colorectal cancer: the promise of chimeric antigen receptor (CAR)-T cells","volume":"22","author":"Aparicio","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh293","article-title":"Outcome prediction and the future of the TNM staging system","volume":"96","author":"Burke","year":"2004","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.0952","article-title":"Revised TN categorization for colon cancer based on national survival outcomes data","volume":"28","author":"Gunderson","year":"2010","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6462-1","article-title":"AJCC 8th edition: colorectal cancer","volume":"25","author":"Weiser","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v123.18","article-title":"Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer","volume":"123","author":"Lee","year":"2017","journal-title":"Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000247","article-title":"Molecular pathology of colorectal cancer","volume":"27","author":"Harada","year":"2020","journal-title":"Adv Anat Pathol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.3390\/cancers13102296","article-title":"The role of p53 dysfunction in colorectal cancer and its implication for therapy","volume":"13","author":"Michel","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1053\/j.gastro.2015.07.011","article-title":"Epigenetic alterations in colorectal cancer: emerging biomarkers","volume":"149","author":"Okugawa","year":"2015","journal-title":"Gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00774","article-title":"Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy","volume":"8","author":"Gao","year":"2017","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1752563","DOI":"10.1080\/2162402X.2020.1752563","article-title":"Efficacy of adjuvant cytokine-induced killer cell immunotherapy in patients with colorectal cancer after radical resection","volume":"9","author":"Pan","year":"2020","journal-title":"Oncoimmunology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2014.07.010","article-title":"Effects of cytokine-induced killer cell treatment in colorectal cancer patients: a retrospective study","volume":"68","author":"Zhang","year":"2014","journal-title":"BioMed Pharmacother"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.693016","article-title":"CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities","volume":"12","author":"Fischer","year":"2021","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-023-00373-7","article-title":"Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment","volume":"12","author":"Yan","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"8996","DOI":"10.3390\/ijms22168996","article-title":"CAR T-cell therapy in hematological Malignancies","volume":"22","author":"Haslauer","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02446-2","article-title":"Beyond the blood: expanding CAR T cell therapy to solid tumors","volume":"12","author":"Uslu","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00384-024-04790-w","article-title":"Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective","volume":"40","author":"Kaviyarasan","year":"2024","journal-title":"Int J Colorectal Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-023-01830-x","article-title":"Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer","volume":"22","author":"Chen","year":"2023","journal-title":"Mol Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"11673","DOI":"10.3390\/ijms241411673","article-title":"T cells in colorectal cancer: unravelling the function of different T cell subsets in the tumor microenvironment","volume":"24","author":"Zheng","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1038\/s41467-019-09415-3","article-title":"Crizotinib-induced immunogenic cell death in non-small cell lung cancer","volume":"10","author":"Liu","year":"2019","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","first-page":"116532","DOI":"10.1016\/j.biopha.2024.116532","article-title":"Efficient combination of radiotherapy and CAR-T - A systematic review","volume":"174","author":"Szlasa","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.813832","article-title":"CAR-T plus radiotherapy: A promising combination for immunosuppressive tumors","volume":"12","author":"Qin","year":"2021","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/s41573-023-00809-z","article-title":"T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome","volume":"22","author":"Klebanoff","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"B31","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/d41573-024-00121-4","article-title":"TCR-boosted T cell therapy yields proof-of-principle clinical data in solid cancer","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.3390\/cells9092095","article-title":"Breaking bottlenecks for the TCR therapy of cancer","volume":"9","author":"Gaissmaier","year":"2020","journal-title":"Cells"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.3390\/cells9071588","article-title":"T-cell gene therapy in cancer immunotherapy: why it is no longer just CARs on the road","volume":"9","author":"Crowther","year":"2020","journal-title":"Cells"},{"key":"B34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.canlet.2016.12.039","article-title":"MHC class II restricted neoantigen: A promising target in tumor immunotherapy","volume":"392","author":"Sun","year":"2017","journal-title":"Cancer Lett"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.835762","article-title":"Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects","volume":"13","author":"Shafer","year":"2022","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.3390\/cancers13164129","article-title":"NK cell therapy: A rising star in cancer treatment","volume":"13","author":"Du","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2012.12.004","article-title":"Ex vivo characterization of \u03b3\u03b4 T-cell repertoire in patients after adoptive transfer of V\u03b39V\u03b42 T cells expressing the interleukin-2 receptor \u03b2-chain and the common \u03b3-chain","volume":"15","author":"Izumi","year":"2013","journal-title":"Cytotherapy"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0879-0","article-title":"Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vgamma9Vdelta2 T lymphocyte agonist in patients with solid tumors","volume":"59","author":"Bennouna","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3109\/14653249.2010.515581","article-title":"Zoledronate-activated V\u03b39\u03b3\u03b4 T cell-based immunotherapy is feasible and restores the impairment of \u03b3\u03b4 T cells in patients with solid tumors","volume":"13","author":"Noguchi","year":"2011","journal-title":"Cytotherapy"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.293","article-title":"Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours","volume":"105","author":"Nicol","year":"2011","journal-title":"Br J Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.175","article-title":"175 High-dose TIL product with improved phenotype and functionality","volume":"9","author":"Friese","year":"2021","journal-title":"J ImmunoTherapy Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-021-00820-y","article-title":"Efficient recovery of potent tumour-infiltrating lymphocytes through quantitative immunomagnetic cell sorting","volume":"6","author":"Wang","year":"2022","journal-title":"Nat BioMed Eng"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-010-0920-8","article-title":"Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer","volume":"17","author":"Karlsson","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006822","article-title":"Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma","volume":"12","author":"Amaria","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/cancers11010047","article-title":"Chimeric antigen receptor T-cell (CAR T) therapy for hematologic and solid Malignancies: efficacy and safety-A systematic review with meta-analysis","volume":"11","author":"Yu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00091-8","article-title":"Clinical significance of combined tumour-infiltrating lymphocytes and microsatellite instability status in colorectal cancer: a systematic review and network meta-analysis","volume":"11","author":"Wankhede","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-2990","article-title":"Macrophage-based approaches for cancer immunotherapy","volume":"81","author":"Anderson","year":"2021","journal-title":"Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41419-024-06616-7","article-title":"Advances in engineered macrophages: A new frontier in cancer immunotherapy","volume":"15","author":"Yang","year":"2024","journal-title":"Cell Death Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783305","article-title":"Engineered CAR-macrophages as adoptive immunotherapies for solid tumors","volume":"12","author":"Sloas","year":"2021","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.730824","article-title":"Recent advances in experimental dendritic cell vaccines for cancer","volume":"11","author":"Filin","year":"2021","journal-title":"Front Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00766","article-title":"Personalized dendritic cell vaccines-recent breakthroughs and encouraging clinical results","volume":"10","author":"Mastelic-Gavillet","year":"2019","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12957-017-1278-1","article-title":"Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment","volume":"15","author":"Xie","year":"2017","journal-title":"World J Surg Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"603871","DOI":"10.1155\/2014\/603871","article-title":"Immune response, safety, and survival and quality of life outcomes for advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced killer cell therapy","volume":"2014","author":"Zhu","year":"2014","journal-title":"BioMed Res Int"},{"key":"B59","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/sj.gt.3302608","article-title":"Dendritic cell therapy with interferon-alpha synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model","volume":"13","author":"Ishii","year":"2006","journal-title":"Gene Ther"},{"key":"B60","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s40425-019-0787-6","article-title":"Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer","volume":"7","author":"Westdorp","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.536700","article-title":"High health-related quality of life during dendritic cell vaccination therapy in patients with castration-resistant prostate cancer","volume":"10","author":"Westdorp","year":"2020","journal-title":"Front Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40425-016-0128-y","article-title":"Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer","volume":"4","author":"Radomski","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"105374","DOI":"10.1016\/j.phrs.2020.105374","article-title":"Dendritic cell vaccine therapy for colorectal cancer","volume":"164","author":"Wooster","year":"2021","journal-title":"Pharmacol Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2138","article-title":"A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival","volume":"16","author":"Barth","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B66","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/978-1-4615-1267-7_24","article-title":"Tumor-associated carbohydrate antigens defining tumor Malignancy: basis for development of anti-cancer vaccines","volume":"491","author":"Hakomori","year":"2001","journal-title":"Adv Exp Med Biol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nature05907","article-title":"CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor","volume":"448","author":"Borg","year":"2007","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/375155a0","article-title":"Natural and synthetic non-peptide antigens recognized by human gamma delta T cells","volume":"375","author":"Tanaka","year":"1995","journal-title":"Nature"},{"key":"B69","doi-asserted-by":"publisher","first-page":"100776","DOI":"10.1016\/j.mcpro.2024.100776","article-title":"(Sialyl)Lewis antigen expression on glycosphingolipids, N-, and O-glycans in colorectal cancer cell lines is linked to a colon-like differentiation program","volume":"23","author":"Wang","year":"2024","journal-title":"Mol Cell Proteomics"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.6b05675","article-title":"Sialyl-tn polysaccharide A1 as an entirely carbohydrate immunogen: synthesis and immunological evaluation","volume":"138","author":"Shi","year":"2016","journal-title":"J Am Chem Soc"},{"key":"B71","article-title":"Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis","volume":"62","author":"Kakiuchi","year":"2002","journal-title":"Cancer Res"},{"key":"B72","article-title":"Role of carcinoembryonic antigen in the progression of colon cancer cells that express carbohydrate antigen","volume":"61","author":"Minami","year":"2001","journal-title":"Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.RA119000236","article-title":"Bacterial immunogenic \u03b1-galactosylceramide identified in the murine large intestine: dependency on diet and inflammation","volume":"60","author":"von Gerichten","year":"2019","journal-title":"J Lipid Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"120716","DOI":"10.1016\/j.talanta.2020.120716","article-title":"Aptamer-based biosensor for detecting carcinoembryonic antigen","volume":"214","author":"Xiang","year":"2020","journal-title":"Talanta"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1039\/D3NR04118B","article-title":"Photoactive imaging and therapy for colorectal cancer using a CEA-Affimer conjugated Foslip nanoparticle","volume":"16","author":"Khaled","year":"2024","journal-title":"Nanoscale"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/jso.v109.5","article-title":"Evaluating the significance of expression of CEA mRNA and levels of CEA and its related proteins in colorectal cancer patients","volume":"109","author":"Wang","year":"2014","journal-title":"J Surg Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2021.03.005","article-title":"Impaired intestinal sodium transport in inflammatory bowel disease: from the passenger to the driver\u2019s seat","volume":"12","author":"Prasad","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93686","article-title":"Guanylate cyclase 2C agonism corrects CFTR mutants","volume":"2","author":"Arora","year":"2017","journal-title":"JCI Insight"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2012.03.022","article-title":"Meconium ileus caused by mutations in GUCY2C, encoding the CFTR-activating guanylate cyclase 2C","volume":"90","author":"Romi","year":"2012","journal-title":"Am J Hum Genet"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/23808993.2021.1876518","article-title":"GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer","volume":"6","author":"Lisby","year":"2021","journal-title":"Expert Rev Precis Med Drug Dev"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00476","article-title":"NKG2D and its ligands: \u201cOne for all, all for one","volume":"9","author":"Alessandra","year":"2018","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41590-020-0643-3","article-title":"Sestrins induce natural killer function in senescent-like CD8+ T cells","volume":"22","author":"Pereira","year":"2020","journal-title":"Nat Immunol"},{"key":"B83","article-title":"Role of NKG2D and its ligands in cancer immunotherapy","volume":"9","author":"Liu","year":"2019","journal-title":"Am J Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","first-page":"a020768","DOI":"10.1101\/cshperspect.a020768","article-title":"The EGFR family: not so prototypical receptor tyrosine kinases","volume":"6","author":"Lemmon","year":"2014","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-024-03559-w","article-title":"Multispectral fluorescence imaging of EGFR and PD-L1 for precision detection of oral squamous cell carcinoma: a preclinical and clinical study","volume":"22","author":"Jin","year":"2024","journal-title":"BMC Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4161\/cc.27518","article-title":"EGFR signaling and autophagy dependence for growth, survival, and therapy resistance","volume":"13","author":"Jutten","year":"2014","journal-title":"Cell Cycle"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2014.11.013","article-title":"mTORC1 phosphorylates UVRAG to negatively regulate autophagosome and endosome maturation","volume":"57","author":"Kim","year":"2015","journal-title":"Mol Cell"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1038\/s41467-023-38318-7","article-title":"TRPV1 inhibition overcomes cisplatin resistance by blocking autophagy-mediated hyperactivation of EGFR signaling pathway","volume":"14","author":"Oh","year":"2023","journal-title":"Nat Commun"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.3390\/ijms24032651","article-title":"Small molecule EGFR inhibitors as anti-cancer agents: discovery, mechanisms of action, and opportunities","volume":"24","author":"Zubair","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3388","article-title":"The quest to overcome resistance to EGFR-targeted therapies in cancer","volume":"19","author":"Chong","year":"2013","journal-title":"Nat Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab231","article-title":"The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis","volume":"24","author":"Youri","year":"2022","journal-title":"Neuro-Oncology"},{"key":"B92","doi-asserted-by":"publisher","first-page":"106606","DOI":"10.1016\/j.phrs.2022.106606","article-title":"MUC1 promotes glioblastoma progression and TMZ resistance by stabilizing EGFRvIII","volume":"187","author":"Tong","year":"2023","journal-title":"Pharmacol Res"},{"key":"B93","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12032-010-9696-8","article-title":"Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis","volume":"28","author":"Guo","year":"2011","journal-title":"Med Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2015.10.025","article-title":"HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers","volume":"11","author":"Li","year":"2016","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020107333","article-title":"A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast","volume":"40","author":"Pal","year":"2021","journal-title":"EMBO J"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy100","article-title":"Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer","volume":"29","author":"Siena","year":"2018","journal-title":"Ann Oncol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"15065","DOI":"10.18632\/oncotarget.v6i17","article-title":"HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer","volume":"6","author":"Styczen","year":"2015","journal-title":"Oncotarget"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000301","article-title":"EpCAM-high liver cancer stem cells resist natural killer cell\u2013mediated cytotoxicity by upregulating CEACAM1","volume":"8","author":"Park","year":"2020","journal-title":"J Immunotherapy Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15604","article-title":"Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD","volume":"43","author":"Mu\u00f1oz-Hern\u00e1ndez","year":"2023","journal-title":"Liver Int"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1038\/s41598-018-20131-8","article-title":"Spatiotemporal patterning of EpCAM is important for murine embryonic endo- and mesodermal differentiation","volume":"8","author":"Sarrach","year":"2018","journal-title":"Sci Rep"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.06.040","article-title":"Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells","volume":"433","author":"Liang","year":"2018","journal-title":"Cancer Lett"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.2174\/1568009618666180102102311","article-title":"Antibody based epCAM targeted therapy of cancer, review and update","volume":"18","author":"Shirin","year":"2018","journal-title":"Curr Cancer Drug Targets"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2014.02.007","article-title":"MUC1: A multifaceted oncoprotein with a key role in cancer progression","volume":"20","author":"Nath","year":"2014","journal-title":"Trends Mol Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1002\/med.2017.37.issue-6","article-title":"Anti-MUC1 aptamer: A potential opportunity for cancer treatment","volume":"37","author":"Nabavinia","year":"2017","journal-title":"Medicinal Res Rev"},{"key":"B105","doi-asserted-by":"publisher","first-page":"110888","DOI":"10.1016\/j.biopha.2020.110888","article-title":"A review on development of MUC1-based cancer vaccine","volume":"132","author":"Gao","year":"2020","journal-title":"Biomedicine Pharmacotherapy"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-024-00816-1","article-title":"Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer","volume":"31","author":"Malla","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2018.10.024","article-title":"The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma","volume":"215","author":"Cho","year":"2019","journal-title":"Pathol - Res Pract"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.12.083","article-title":"Serum tumor-associated glycoprotein 72, a helpful predictor of lymph nodes invasion in esophagogastric junction adenocarcinoma","volume":"509","author":"Xu","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S253369","article-title":"Biochemical markers of colorectal cancer - present and future","volume":"12","author":"Jelski","year":"2020","journal-title":"Cancer Manage Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2018.10.024","article-title":"The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma","volume":"215","author":"Cho","year":"2019","journal-title":"Pathol Res Pract"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.06.006","article-title":"Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T&xa0;cells","volume":"31","author":"Haas","year":"2023","journal-title":"Mol Ther"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01367-8","article-title":"Targeting mesothelin in solid tumours: anti-mesothelin antibody and drug conjugates","volume":"25","author":"Chu","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-targeted CARs: driving T cells to solid tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11290","article-title":"Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer","volume":"19","author":"Inoue","year":"2020","journal-title":"Oncol Lett"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.808300","article-title":"Role of CD133\/NRF2 axis in the development of colon cancer stem cell-like properties","volume":"11","author":"Park","year":"2022","journal-title":"Front Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.21873\/invivo.11600","article-title":"Immunohistochemical expression of CD133 and LGR5 in ulcerative colitis-associated colorectal cancer and dysplasia","volume":"33","author":"Kazama","year":"2019","journal-title":"In Vivo (Athens Greece)"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.13686","article-title":"Silencing of CD133 inhibits GLUT1-mediated glucose transport through downregulation of the HER3\/Akt\/mTOR pathway in colon cancer","volume":"594","author":"Kim","year":"2020","journal-title":"FEBS Lett"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00849.x","article-title":"Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study","volume":"99","author":"Kojima","year":"2008","journal-title":"Cancer Sci"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2018.02.013","article-title":"c-MET overexpression in colorectal cancer: A poor prognostic factor for survival","volume":"17","author":"Lee","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01503-1","article-title":"Molecular mechanism(s) of regulation(s) of c-MET\/HGF signaling in head and neck cancer","volume":"21","author":"Raj","year":"2022","journal-title":"Mol Cancer"},{"key":"B121","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.eururo.2023.06.008","article-title":"Prostate-specific membrane antigen reporting and data system version 2.0","volume":"84","author":"Werner","year":"2023","journal-title":"Eur Urol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233312","article-title":"PET imaging quantifying ga-68-PSMA-11 uptake in metastatic colorectal cancer","volume":"61","author":"Cuda","year":"2020","journal-title":"J Nucl Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2009.06.003","article-title":"Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers","volume":"40","author":"Haffner","year":"2009","journal-title":"Hum Pathol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.v7.6","article-title":"Pattern of placental alkaline phosphatase (PLAP) expression in human tumors: a tissue microarray study on 12,381 tumors","volume":"7","author":"Reiswich","year":"2021","journal-title":"J Pathol Clin Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.0c00860","article-title":"Alkaline phosphatases: in silico study on the catalytic effect of conserved active site residues using human placental alkaline phosphatase (PLAP) as a model protein","volume":"60","author":"Borosky","year":"2020","journal-title":"J Chem Inf Modeling"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.2741\/4877","article-title":"PLAP -CAR Tcells mediate high specific cytotoxicity against colon cancer cells","volume":"25","author":"Li","year":"2020","journal-title":"FBL"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00247-z","article-title":"Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer","volume":"2","author":"Westcott","year":"2021","journal-title":"Nat Cancer"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i48.5418","article-title":"Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens","volume":"24","author":"Wagner","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.v13.11","article-title":"Personalised neoantigen-based therapy in colorectal cancer","volume":"13","author":"Zhu","year":"2023","journal-title":"Clin Transl Med"},{"key":"B130","doi-asserted-by":"publisher","first-page":"8270305","DOI":"10.1155\/2022\/8270305","article-title":"Neoantigen: A promising target for the immunotherapy of colorectal cancer","volume":"2022","author":"Zheng","year":"2022","journal-title":"Dis Markers"},{"key":"B131","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/(ISSN)1097-0215","article-title":"Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens","volume":"93","author":"Linnebacher","year":"2001","journal-title":"Int J Cancer"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2021.1891814","article-title":"Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer","volume":"18","author":"Yu","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600697","article-title":"Specific T-cell immunity against Ki-ras peptides in patients with pancreatic and colorectal cancers","volume":"88","author":"Shono","year":"2003","journal-title":"Br J Cancer"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0314","article-title":"The HIF-1\u03b1 hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy","volume":"2","author":"Palaz\u00f3n","year":"2012","journal-title":"Cancer Discov"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00207.2015","article-title":"Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia","volume":"309","author":"Noman","year":"2015","journal-title":"Am J Physiol Cell Physiol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.03.026","article-title":"HIF-1 inhibitor-based one-stone-two-birds strategy for enhanced cancer chemodynamic-immunotherapy","volume":"356","author":"Zhang","year":"2023","journal-title":"J Control Release"},{"key":"B137","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.semcancer.2014.08.002","article-title":"Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use","volume":"31","author":"Pastorek","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01237","article-title":"Lipoyl-homotaurine derivative (ADM_12) reverts oxaliplatin-induced neuropathy and reduces cancer cells Malignancy by inhibiting carbonic anhydrase IX (CAIX)","volume":"60","author":"Fragai","year":"2017","journal-title":"J Medicinal Chem"},{"key":"B139","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051424","article-title":"Effector memory T cells, early metastasis, and survival in colorectal cancer","volume":"353","author":"Pag\u00e8s","year":"2005","journal-title":"N Engl J Med"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0145","article-title":"The colorectal cancer immune microenvironment and approach to immunotherapies","volume":"13","author":"Koi","year":"2017","journal-title":"Future Oncol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3390\/cancers6031670","article-title":"Tumor-associated macrophages as major players in the tumor microenvironment","volume":"6","author":"Chanmee","year":"2014","journal-title":"Cancers (Basel)"},{"key":"B143","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/cac2.12295","article-title":"Cytokine-and chemokine-induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy","volume":"42","author":"Bhat","year":"2022","journal-title":"Cancer Commun"},{"key":"B144","doi-asserted-by":"publisher","first-page":"102113","DOI":"10.1016\/j.tranon.2024.102113","article-title":"Collagen extracellular matrix promotes gastric cancer immune evasion by activating IL4I1-AHR signaling","volume":"49","author":"Zhang","year":"2024","journal-title":"Trans Oncol"},{"key":"B145","article-title":"Development of innovative CAR molecules to be transduced in Cytokine Induced Killer cells for the treatment of different neoplasia","author":"Zaninelli","year":"2023"},{"key":"B146","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.3390\/cancers13143466","article-title":"Extracellular matrices and cancer-associated fibroblasts: targets for cancer diagnosis and therapy","volume":"13","author":"Belhabib","year":"2021","journal-title":"Cancers"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2086","article-title":"Targeting the Hedgehog pathway in cancer","volume":"5","author":"Rubin","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.904137","article-title":"Recent advances in CAR-T cells therapy for colorectal cancer","volume":"13","author":"Qin","year":"2022","journal-title":"Front Immunol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.3390\/biomedicines11092361","article-title":"Cellular and molecular mechanisms of the tumor stroma in colorectal cancer: insights into disease progression and therapeutic targets","volume":"11","author":"Shakhpazyan","year":"2023","journal-title":"Biomedicines"},{"key":"B150","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41419-024-06697-4","article-title":"Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy","volume":"15","author":"Mai","year":"2024","journal-title":"Cell Death Dis"},{"key":"B151","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/s41467-025-56527-0","article-title":"Unlocking the potential of engineered immune cell therapy for solid tumors","volume":"16","author":"Albarr\u00e1n-Fern\u00e1ndez","year":"2025","journal-title":"Nat Commun"},{"key":"B152","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","article-title":"Engineering T cells with customized therapeutic response programs using synthetic notch receptors","volume":"167","author":"Roybal","year":"2016","journal-title":"Cell"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1624","article-title":"Synthetic cytokine circuits that drive T cells into immune-excluded tumors","volume":"378","author":"Allen","year":"2022","journal-title":"Science"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq6990","article-title":"The future of engineered immune cell therapies","volume":"378","author":"Irvine","year":"2022","journal-title":"Science"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"B156","doi-asserted-by":"publisher","first-page":"176618","DOI":"10.1016\/j.ejphar.2024.176618","article-title":"Improving chimeric antigen receptor T-cell therapies by using artificial intelligence and internet of things technologies: A narrative review","volume":"974","author":"Boretti","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s12967-022-03765-1","article-title":"Integration of CRISPR\/Cas9 with artificial intelligence for improved cancer therapeutics","volume":"20","author":"Bhat","year":"2022","journal-title":"J Transl Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1557906\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T04:12:22Z","timestamp":1743480742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1557906\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":157,"alternative-id":["10.3389\/fimmu.2025.1557906"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1557906","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"article-number":"1557906"}}